DUBLIN, April 28, 2025--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield ("Anthem") has established favorable coverage for the company’s ReActiv8 ...

DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the ...

ReActiv8 is now supported by the most complete and robust set of clinical evidence of any neuromodulation therapy for axial back pain globally. The study included 203 patients, with 99 randomized into ...

Mechanical chronic low back pain results from an injury or stress on the tissues surrounding the spine, including soft tissues, muscles, bones, and joints. Often, this type of pain is due to impaired ...

ReActiv8 is designed to electrically stimulate the nerves responsible for contracting muscles which stabilize the lumbar spine. Activation of these muscles to restore functional stability has been ...

Anyone living with chronic low back pain frequently has one wish on their mind: “Fix. My. Lower. Back.” Now, a new clinically proven restorative treatment option called ReActiv8 could make a ...

Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative ...

The Food and Drug Administration (FDA) has approved ReActiv8® (Mainstay Medical), an implantable neurostimulation system, for the treatment of intractable chronic low back pain. Specifically, the ...

Chronic lower back pain is something that can dramatically affect a person’s lifestyle and wellbeing. Whilst most back pain only lasts a short while and can be treated with medication or physiotherapy ...